#### **SUPPLEMENTARY PROSPECTUS DATED 2 MAY 2025**



#### **NatWest Markets Plc**

(Incorporated in Scotland with limited liability under the Companies Acts 1948 to 1980, registered number SC090312)

# £20,000,000,000 Euro Medium Term Note Programme

# US\$10,000,000,000 US Medium-Term Note Programme

This supplement (the "Supplementary Prospectus") to (i) the base prospectus dated 6 December 2024 relating to the £20,000,000,000 Euro Medium Term Note Programme established by NatWest Markets Plc (the "Issuer" or "NatWest Markets") (as supplemented, the "EMTN Prospectus") and (ii) the base prospectus dated 17 March 2025 relating to the US\$10,000,000,000 US Medium-Term Note Programme established by the Issuer (the "USMTN Prospectus" and together with the EMTN Prospectus, the "Prospectuses" and each a "Prospectus"), each of which comprises a base prospectus for the purpose of Regulation (EU) 2017/1129 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the "UK Prospectus Regulation"), constitutes a supplementary prospectus for the purposes of Article 23 of the UK Prospectus Regulation.

Terms defined in each Prospectus have the same meaning when used in this Supplementary Prospectus.

This Supplementary Prospectus constitutes the 4<sup>th</sup> Supplementary Prospectus in respect of the EMTN Prospectus and the 2<sup>nd</sup> Supplementary Prospectus in respect of the USMTN Prospectus.

This Supplementary Prospectus is supplemental to, and should be read in conjunction with, each Prospectus and the documents incorporated by reference therein.

This Supplementary Prospectus has been approved by the United Kingdom Financial Conduct Authority (the "FCA"), as competent authority under the UK Prospectus Regulation. The FCA only approves this Supplementary Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the UK Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer that is the subject of this Supplementary Prospectus. With effect from the date of this Supplementary Prospectus the information appearing in, or incorporated by reference into, each Prospectus shall be supplemented in the manner described below.

The Issuer accepts responsibility for the information contained in this Supplementary Prospectus. To the best of the knowledge of the Issuer such information is in accordance with the facts and makes no omission likely to affect its import.

The distribution of this Supplementary Prospectus and the offer or sale of any securities of the Issuer may be restricted by law in certain jurisdictions. Persons into whose possession this Supplementary Prospectus or any securities of the Issuer come must inform themselves about, and observe, any such restrictions.

Any securities to be issued by the Issuer in connection with this Supplementary Prospectus and the Prospectuses have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction of the US. Accordingly, any such securities may not be offered, sold, pledged or otherwise transferred within the US or to or for the account or benefit of US persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable state securities laws. There will be no public offering of securities in the United States.

# **Purpose of the Supplementary Prospectus**

The purpose of this Supplementary Prospectus is to:

- (a) incorporate by reference into each Prospectus:
  - (i) the NWM Group Q1 2025 IMS (as defined below);
  - (ii) the 2<sup>nd</sup> Supplementary Registration Document (as defined below); and
  - (iii) the April 2025 Directorate Changes Announcement (as defined below);
- (b) following publication of the NWM Group Q1 2025 IMS, update the statement of no significant change;
- (c) update certain information in relation to legal proceedings; and
- (d) update certain information relating to capitalisation of NatWest Markets in respect of the USMTN Prospectus.

# Incorporation of Information by Reference

By virtue of this Supplementary Prospectus:

- (a) the unaudited Q1 2025 Interim Management Statement of the Issuer (the "NWM Group Q1 2025 IMS"), which was published via the regulatory news service of the London Stock Exchange on 2 May 2025;
- (b) the Issuer's second supplementary registration document dated 2 May 2025 (the "2<sup>nd</sup> Supplementary Registration Document"), which was published via the regulatory news service of the London Stock Exchange on 2 May 2025; and
- (c) the announcement entitled "NatWest Group plc and NatWest Markets Plc Directorate Changes" (the "April 2025 Directorate Changes Announcement"), which was published via the regulatory news service of the London Stock Exchange plc on 14 April 2025,

each of which has been (1) previously published and (2) filed with the Financial Conduct Authority, shall be incorporated in, and form part of, each Prospectus.

For at least ten years from the date of each Prospectus, a copy of any or all of the information which is incorporated by reference in the Prospectuses will be able to be obtained from the website of NatWest Group plc at <a href="https://investors.natwestgroup.com/regulatory-news/company-announcements">https://investors.natwestgroup.com/regulatory-news/company-announcements</a> and from the London Stock Exchange plc's website at <a href="https://www.londonstockexchange.com/news">www.londonstockexchange.com/news</a>.

If a document which is incorporated by reference in the Prospectuses by virtue of this Supplementary Prospectus itself incorporates any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of the Prospectuses except where such information or other documents are specifically incorporated by reference in, or attached to, each Prospectus by virtue of this Supplementary Prospectus.

## Statement of No Significant Change

There has been no significant change in the financial position or financial performance of the NWM Group taken as a whole since 31 March 2025 (the end of the last financial period for which the latest interim financial information of the NWM Group has been published).

#### Updating the legal proceedings disclosure set out in the Prospectuses

The section entitled "Description of the Issuer – Legal Proceedings" on page 84 of the EMTN Prospectus shall be deleted and replaced with the following:

# "Legal Proceedings

For a description of the material governmental, legal or arbitration proceedings that NatWest Markets and the NWM Group face, see the section entitled "*Litigation and Regulatory Matters*" at pages 98 to 103 of the Registration Document (as supplemented by the 2<sup>nd</sup> Supplementary Registration Document) as referred to in, and incorporated by reference into, this Prospectus.".

#### **Legal Proceedings**

Other than as referred to in the section entitled "Litigation and Regulatory Matters" of the Registration Document (as supplemented by the 2<sup>nd</sup> Supplementary Registration Document), there are no governmental, legal or arbitration proceedings (including any such proceedings which are pending or threatened of which the Issuer is aware), which may have or have had during the 12 months preceding the date of this Supplementary Prospectus, a significant effect on the financial position or profitability of NatWest Markets and/or the NWM Group.

## Updating the capitalisation disclosure set out in the USMTN Prospectus

The section entitled "Capitalisation" on page 35 of the USMTN Prospectus shall be deleted and replaced with the following:

#### "

## CAPITALISATION

The following table sets forth, as at 31 March 2025, the Issuer's consolidated capitalisation and indebtedness:

A a a t

	As at
	31 March 2025
<del>-</del>	£m
Bank deposits – amortised cost (including repos)	4,496
Customer deposits – amortised cost	5,940
Trading liabilities <sup>(1)</sup>	45,383
of which: repo	32,659
of which: debt securities in issue	259
of which: other deposits	881
of which: derivative cash collateral received	11,584
Other financial liabilities	32,876
of which: customer deposits – designated fair value	1,752
of which: debt securities in issue	30,857
of which: subordinated liabilities	267
Amounts due to holding company and fellow subsidiaries <sup>(2)</sup>	6,519
of which: Internal MREL instruments issued to NatWest Group plc	4,234
of which: other bank and customer deposits	1,174
of which: subordinated liabilities	1,111
Total senior funding and subordinated liabilities(3)	95,214
Total owner's equity	7,215
Non-controlling interests	0

Total equity	7,215
Total senior funding, subordinated liabilities and equity	102,429

<sup>(1)</sup> Funding sources excludes short positions of £11,992 million reflected as trading liabilities on the balance sheet.

The table above should be read in conjunction with the financial statements incorporated by reference into this Base Prospectus.

The Issuer regularly considers various market funding options and accesses the debt capital markets in a variety of issuance formats, currencies and tenors from time to time in connection with executing its funding plans. In addition, the Issuer may from time to time issue capital instruments and loss-absorbing senior debt to its parent, NatWest Group plc, or downstream capital instruments and loss-absorbing senior debt to its subsidiaries.".

#### Other Information

To the extent that there is any inconsistency between any statement in this Supplementary Prospectus and any other statement in or incorporated by reference in each Prospectus, the statements in this Supplementary Prospectus will prevail.

Save as disclosed in this Supplementary Prospectus no other significant new factor, material mistake or material inaccuracy relating to information included in each Prospectus has arisen or been noted, as the case may be, since the publication of the Prospectuses.

The hyperlinks included in this Supplementary Prospectus are included for information purposes only and the websites and their content are not incorporated into, and do not form part of, this Supplementary Prospectus or the Prospectuses.

<sup>(2)</sup> Funding sources excludes other liabilities of £77 million reflected as amounts due to holding company and fellow subsidiaries on the balance sheet.

<sup>(3)</sup> Funding sources excludes settlement balances of £9,083 million, derivatives of £56,284 million and other liabilities of £550 million reflected as liabilities on the balance sheet.